

Request for Prior Authorization Sepiapterin (Sephience)

FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name		DOB		
Patient address	I				
Provider NPI	Prescriber name		Phone		
Prescriber address			Fax		
Pharmacy name	Address		Phone		
Prescriber must complete all informa	ation above. It must be legible, co	rrect, and complete or	form will be returned.		
Pharmacy NPI	Pharmacy fax	NDC 			
Prior authorization (PA) is require compendia indicated diagnosis for					
 Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and 					
2. Patient has a diagnosis of hyperphenylalaninemia (HPA) with sepiapterin-responsive phenylketonuria (PK); and					
3. Patient is on a phenylalanine (Phe) restricted diet prior to therapy and will continue throughout therapy; an					
4. Patient has a baseline blood Phe level ≥ 360 μmol/L while following a Phe restricted diet, obtained within 2 weeks of initiation of sepiapterin therapy (attach lab results); and					
5. Patient's current weight in kg is provided; and					
6. Blood Phe levels will be measured after 2 weeks of therapy and at least one more time before initial renewal; and					
7. Is not prescribed concurrently with sapropterin (Kuvan) or pegvaliase-pqpz (Palynziq).					
Initial requests will be considered for 2 months to assess response to therapy.					
Continuation of therapy will be considered when the following criteria are met:					
1. Patient's current weight in kg is provided; and					
2. Patient continues a Phe restricted diet; and					
		d Phe level does not	decrease at maximum dose, the		
4. Patient continues to respond to and	therapy as demonstrated by a re	duction in Phe blood	levels since initiation of therapy;		
5. Is not prescribed concurrently	with sapropterin (Kuvan) or peg	valiase-pqpz (Palynzi	q).		
Non-Preferred					
Sephience					
Strength	Usage Instructions	Quantity	Day's Supply		
Diagnosis:					

470-0245 (1/26) Page 1 of 2

Request for Prior Authorization Sepiapterin (Sephience)

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Is patient on a phenylalanine (Phe) restricted diet prior	to therapy and	will continue throughout therapy?
□ Yes		
□ No		
Does patient have a baseline blood Phe level ≥ 360 μm within 2 weeks of initiation of sepiapterin therapy?	ol/L while follo	wing a Phe restricted diet, obtained
☐ Yes, attach results☐ No		
Patient's current weight in kg:	Date obtained	d:
Will blood Phe levels be measured after 2 weeks of the renewal? ☐ Yes ☐ No	rapy and at lea	est one more time before initial
Will sepiapterin be prescribed concurrently with sapro	pterin (Kuvan)	or pegvaliase-pqpz (Palynziq)?
□ Yes □ No		
Renewal Requests		
Patient's current weight in kg:	Date obtained	d:
Is patient continuing a phenylalanine (Phe) restricted d	liet?	
□ Yes		
□ No		
Provide updated blood Phe level documenting respon	se to therapy	of at least a 30% reduction in Phe
level: Date obtained:		
Does patient continue to respond to therapy as demorinitiation of therapy?	nstrated by a r	eduction in Phe blood levels since
□ Yes □ No		
Is sepiapterin prescribed concurrently with sapropterin ☐ Yes ☐ No	ı (Kuvan) or pe	egvaliase-pqpz (Palynziq)?
Attach lab results and other documentation as necessary.		
Prescriber signature (Must match prescriber listed above.)		Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization, the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary, by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

470-0245 (1/26) Page 2 of 2